Akhil Santhosh, Medical Oncology Specialist at MVR Cancer Centre and Research Institute, shared a post on X:
“Long term follow up of CM 577 in Esophageal Cancer:
- Median OS 51.3m in adj nivolumab arm vs 35.3m in placebo
- only numerical improvement in OS (not statistically sig).
Benefit more for PDL1>1 and squamous subset, end of the road for CROSS and CM 577?”
More posts featuring Akhil Santhosh on OncoDaily.